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AbstrAct:
Due to an increase in the prevalence of chronic diseases, medication use and their cost is rising rapidly. This scenario 
render chronic patients at an increased risk of experiencing drug therapy problems, subsequently leading to unfavourable 
clinical and economic outcomes. Thus, to ensure patients’ optimal medication use and improve their clinical outcomes, 
a comprehensive and systematic management of medications is deemed crucial. Hence, Comprehensive Medication 
Management (CMM) services offered by trained pharmacists can fill this gap by decreasing the unnecessary and often 
harmful use of medicines and consequent resulting complications. Collaborative practice between pharmacists and gen-
eral practitioners, together with patients’ active participation in the definition of treatment regimens, plays an important 
role in the effectiveness of CMM services. CMM services is defined as the standard of care that ensures each patient’s 
medications (prescription, non-prescription, alternative, traditional, vitamins, or nutritional supplements) are individ-
ually assessed to determine that each medication is appropriate for the patient, effective for the medical condition, safe 
given the comorbidities and other medications taken, and that the patient is able to take them as intended. It includes 
an individualized care plan that achieves the intended goals of therapy with appropriate follow-up to determine actual 
patient outcomes.
Apart from the USA, several countries (e.g. Australia, Canada and Brazil) have managed to integrate CMM services 
into their existing health care system at the primary care level. However, in Europe, in spite of the widespread recog-
nition of the need for medication management services, initiation and implementation of CMM services are lagging 
behind. Hence, for CMM services to become a reality in Europe and elsewhere, numerous prerequisites need to be 
accomplished, including policies and legal regulations supporting the provision of CMM services on a much larger scale, 
clearly defined and standardized professional practice and common language shared among the pharmacists, and well 
trained and experienced practitioners providing full-time, direct patient care.
Keywords: medication management, comprehensive medication management services, chronic diseases, pharma-
ceutical care
Sažetak:
Sveobuhvatna uSluga upravljanja farmakoterapijom kao rješenje za propuSte u propiSivanju
lijekova: europSka perSpektiva
Zbog porasta prevalencije kroničnih bolesti, potrošnja lijekova ubrzano raste. Uslijed toga, kronični bolesnici su izloženi 
povećanom riziku pojave terapijskih problema što dovodi do nepovoljnih kliničkih i ekonomskih ishoda liječenja. Stoga 
se smatra da je sveobuhvatno i sustavno upravljanje farmakoterapijom ključno za osiguranje optimalne uporabe lijekova 
kao i za poboljšanje kliničkih ishoda liječenja. Sveobuhvatna usluga upravljanja farmakoterapijom (engl. Comprehensive 
Medication Management Services, CMM services) koju provode posebno educirani ljekarnici može ponuditi rješenje 
za ovaj problem, smanjujući nepotrebnu, a često i štetnu primjenu lijekova te njene posljedične komplikacije. Kolab-
orativna praksa ljekarnika i liječnika obiteljske medicine, koja uključuje i aktivno sudjelovanje pacijenata u kreiranju 
terapijskih režima, važan je čimbenik koji doprinosi učinkovitosti CMM usluge. CMM usluga se definira kao standard 
skrbi koji osigurava da se svakom pacijentu pojedinačno procjenjuju svi lijekovi (u receptnom ili bezreceptnom režimu, 
biljni, tradicionalni), vitamini ili dodaci prehrani koje uzima, kako bi se za svaki od njih utvrdilo je li prikladan za 
pacijenta, je li učinkovit za pacijentovo zdravstveno stanje, je li siguran s obzirom na komorbiditete i druge lijekove koje 
pacijent uzima, te je li pacijent sposoban i u mogućnosti uzimati lijekove kako treba. Usluga sadrži individualizirani plan 
skrbi kojim se postižu predviđeni ciljevi terapije kao i odgovarajuće praćenje (follow-up) kako bi se utvrdili stvarni ishodi 
liječenja.
Pored SAD-a, nekoliko je drugih zemalja (Australija, Kanada i Brazil) uspjelo integrirati CMM uslugu u svoje postojeće 
sustave primarne zdravstvene zaštite. Međutim, u Europi, unatoč raširenosti spoznaje o potrebi za upravljanjem far-
makoterapijom, razvoj i implementacija CMM usluge  zaostaje. Kako bi se CMM usluge realizirale u Europi i ostalim 
zemljama, potrebno je ispuniti brojne preduvjete, uključujući donošenje politika i zakonskih propisa koji podržavaju 
pružanje CMM usluga u mnogo većem obimu, ostvarivanje jasno definirane i standardizirane profesionalne prakse i 
zajedničkog jezika ljekarnika, te stvaranje dobro educiranih i iskusnih ljekarnika koji u punom radnom vremenu pružaju 
izravnu skrb pacijentima.
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introduction
According to the 2018 World Health Organization Country Profiles, 
noncommunicable diseases are the leading cause of death globally, 
and one of the major health challenges of the 21st century1. In 2016, 
they were responsible for 71% (41 million) of the deaths globally, 
with cardiovascular diseases, cancers, chronic respiratory diseases and 
diabetes being the major causes1. Due to an increase in the prevalence 
of chronic illnesses, the number of prescriptions as well as their cost 
is rising rapidly2,3. The latest OECD publication “Health at a Glance: 
Europe 2018” states that pharmaceuticals expenditure represents the 
third largest item of health care spending in the European Union 
(EU), with Croatia having one of the highest expenditures on medical 
goods (mainly pharmaceuticals) among the EU Member States4. 
Moreover, an ample evidence base suggests that patients are often 
inadequately treated or not offered therapies that are likely to bring 
benefit4,5. Consequently, patients are at an increased risk of experi-
encing drug therapy problems (DTPs) which, if not resolved, have 
substantial unfavourable clinical repercussions and add substantial 
costs to the health care system6-8. 
One way to address these issues is by improving the health-care system 
delivery and medication management.  This includes, but is not lim-
ited to, the use of multidisciplinary care teams to provide coordinated 
care and ensure safe and effective pharmacotherapy to patients9. 
Comprehensive Medication Management (CMM) services offered by 
trained pharmacists can fill this gap by decreasing the unnecessary and 
often harmful use of medicines and consequent resulting complica-
tions2,10-13. 
Today there is a widely accepted notion that a patient care process 
must involve a professional who is capable of applying a logical, 
standardized and reproducible process to pharmacotherapy decisions 
14. When medications were fewer in number, less complicated and 
more manageable, physicians were able to fulfil this responsibility. 
However, this is no longer true. CMM services are supported by a vast 
evidence-based literature6,10-13,15 and grounded in the practice of phar-
maceutical care, as proposed by Cipolle, Strand and Morley14,16,17. It is 
also promoted by several organizations such as the American College 
of Clinical Pharmacy18,19, Get the Medications Right Institute20, and 
Patient-Centered Primary Care Collaborative, which includes more 
than 500 organisations, all active stakeholders in the health-care sys-
tem2. Thus, this service has a scientific and clinical base that attempts 
to systematize the work of the clinical pharmacist with the patient and 
in collaboration with other providers, in order to optimize the use of 
medications in individuals’ daily lives.
the need for Medication ManageMent ServiceS
Over the past few decades, the use of medications has undergone 
significant changes ranging from increases in prescription numbers, 
increases in the number and type of practitioners with prescribing 
rights, rising costs of new medications, to the rise in the increasing-
ly complex new and emerging therapies. Another important factor 
worth mentioning is the continued lack of a structured, systematic 
decision-making process for drug selection and dosing14.
Existing evidence suggests that as much as one-fifth of all health 
spending is wasteful and could be reduced, or eliminated, without 
undermining health system performance21. In fact, after inpatient and 
outpatient care, pharmaceuticals (excluding those used in hospitals) 
represented the third largest health care expense, accounting for one 
sixth of all health expenditure in the EU in 2016. The total retail 
pharmaceutical bill across the EU was more than EUR 210 billion 
in 2016, representing an increase of approximately 5% (in nominal 
terms) since 2010. In Croatia, prescription medications accounted for 
87 - 90% of all medications financial costs from 2012 to 2016, grow-
ing about 3.5% annually, and reaching its peak of 10.2% in 2016 
(22). These trends indicate a need to manage the use of prescription 
medications more efficiently. 
Inadequate medication management has other consequences, such 
as increased levels of drug-related morbidity and mortality, which 
are directly responsible for health care costs, and call for health-care 
system reform14. 
According to the latest data, more than 1.2 million people in EU 
countries died in 2015 from diseases and injuries that could have 
been avoided either through stronger public health policies or more 
effective and timely health care4. Additionally, potentially avoidable 
hospital admissions for some chronic conditions, out of which diabe-
tes, hypertension, heart failure, chronic obstructive pulmonary disease 
(COPD) and bronchiectasis and asthma stand out, consume over 37 
million bed days each year23. Over 4.6 million admissions were made 
for these five conditions in 2015, amounting to 5.6% of all admis-
sions which might have been avoided4. The estimated annual cost of 
drug-related morbidity and mortality resulting from nonoptimized 
medication therapy in the United States (US) was $528.4 billion, 
equivalent to 16% of total US health care expenditures in 20166. 
Thus, governments and health plans pay for poor adherence to treat-
ment, the lack of control of chronic diseases, and the development 
of complications in the long term. Additionally, in cases of multiple 
comorbidities, visits to different medical specialists concurrently, and 
without coordination or communication among them, often contrib-
ute to the worsening of medication related problems.
Hence, the expansion of CMM programs led by clinical pharmacists 
in collaboration with physicians and other licensed prescribers has 
been recommended in the United States as an effective and scalable 
approach to mitigate these avoidable costs and improve patient 
outcomes6. 
Medication ManageMent ServiceS aS a Solution to the 
ProbleM
A definition of medication management services
Comprehensive medication management services is defined as the 
standard of care that ensures each patient’s medications (whether they 
are prescription, nonprescription, alternative, traditional, vitamins, 
or nutritional supplements) are individually assessed to determine 
that each medication is appropriate for the patient, effective for the 
medical condition, safe given the comorbidities and other medications 
taken, and that the patient is able to take them as intended2. The con-
cept and definition of the service has evolved over the years. In 2003, 
the Center for Medicare and Medicaid Services recommended the 
provision of medication therapy management services as an additional 
new service required for patients receiving Medicare Part D bene-
fits2,24. There are a number of definitions for medication management 
services available, but today we rely on the definitions proposed by 
the Patient Centered Primary Care Collaborative2, American Medical 
Association25, and the Minnesota State Legislature26.
CMM services is an evidence-based and patient-centered clinical prac-
tice, provided by pharmacist with an aim of preventing, identifying 
and resolving DTPs to optimize patients’ medication experience and 
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clinical outcomes. Through this rational and standardized process, the 
pharmacist reviews the medications used by the patient and identifies 
possible problems associated with the indication, effectiveness, safety 
and compliance with the pharmacotherapy treatment. In addition to 
the comprehensive assessment of patient’s drug-related needs, CMM 
includes the development of an individualized care plan to determine 
desired goals of therapy with the patient, as well as appropriate fol-
low-up to evaluate actual patient outcomes that result from the care 
plan. All of this occurs because the patient understands, agrees with, 
and actively participates in the treatment regimen, thus optimizing 
each patient’s medication experience and clinical outcomes. 
The CMM services delivered in a health centre has the following five 
elements in common: a) the service needs to be delivered directly to 
a specific patient (as opposed to performing a prescription review 
without seeing the patient); b) it must include an assessment of the 
patient’s medication-related needs, followed by an individualized care 
plan and follow up; c) the care must be comprehensive, i.e. pharma-
ceutical care practitioner assesses all of the patient’s medications (pre-
scribed, over-the-counter, supplements, herbal remedies etc.), since 
medications interact with other medications and impact all medical 
conditions; d) the work of pharmacists needs to be coordinated with 
physicians and other team members: and e) the service is expected to 
add unique value to the care of the patient.
The interventions proposed within the CMM services are grounded 
in the philosophy and ethics of the professional practice of pharma-
ceutical care and delivered according to the standards of practice for 
the patient care process described by the practice14. Pharmaceutical 
care was defined in 1990 as a practice in which a pharmacist-prac-
titioner is held responsible for patient’s drug related needs and 
accountable for this commitment, providing rational drug therapy 
with the purpose of achieving positive patient outcomes27. 
how iS cMM delivered?
CMM is a patient-centred clinical service offered by pharmacists spe-
cially trained to do so. The pharmacist works directly with the patient 
in collaboration with physicians and other members of the multi-
disciplinary health care team. Care is coordinated among providers 
and across systems of care as patients transition in and out of various 
settings. Detailed description of steps and activities that need to be 
completed in order to carry out complete CMM services, including 
the patient care process, is presented in Table 1. 
The three steps of the patient care process include a) the assessment of 
the patient, his or her medical problems, and drug therapies leading 
to the DTP identification, b) care plan development and c) follow-up 
evaluations. These steps are highly dependent upon each other, and 
the fulfilment of all steps is necessary to practice pharmaceutical care 
and to have positive impact on patient’s medication experience. The 
assessment step in the patient care process is the most important of 
the three as it influences all other components of the patient care pro-
cess. The primary purpose of the assessment is to determine to what 
extent the patient’s drug-related needs are being met and if any DTPs 
are present, while the goal of the care plan development is to deter-
mine how to manage patients’ medical conditions favourably with 
pharmacotherapy. Finally, follow-up evaluation aims to determine the 
actual outcomes of drug therapy for the patient, compare these results 
with the intended goals of therapy, determine the effectiveness and 
safety of pharmacotherapy, evaluate patient adherence, and establish 
the current status of the patient’s medical conditions being managed 
with drug therapy14. All the steps in the care process of the CMM ser-
vices must be documented in a manner that adds unique value to the 
care of the patient, and contain information about the patient, the 
clinical pharmacist’s interventions and decisions, as well as the results 
achieved in the management of pharmacotherapy.
As all patient care providers need a structured, rational thought 
process for sound clinical decision retrieval, the Pharmacotherapy 
Workup was developed and adopted as a systematic problem-solving 
process, specific to the practice of pharmaceutical care. This pro-
cess represents the cognitive work, taking place in the mind of the 
practitioner, and is used to identify, resolve, and prevent drug therapy 
problems (DTPs), establish therapy goals, select interventions and 
evaluate outcomes. As highlighted by Cipolle et al14, what makes 
a practitioner qualified to do her/his work is the application of a 
unique knowledge base and set of clinical skills by using a system-
atic thought process, and in the case of the pharmaceutical care 
practitioner, this unique knowledge base focuses on pharmacology, 
pharmacotherapy, and pharmaceutical care practice.
the value of Medication ManageMent ServiceS
The benefits of CMM services are numerous and include improved 
clinical outcomes11,12,15,28-32, decreased medical costs17,32-34, better 
access to health care services, time-savings to other health care provid-
ers, reduced adverse drug events, as well as significant impact on the 
appropriateness, effectiveness, safety and compliance with medica-
tions18.
The ability of CMM to improve patient outcomes and provide 
system-wide benefits has been well documented35. Early results from 
a high-risk population involving 1651 patients, seen during 4453 en-
counters, show positive results: the percentage of medical conditions 
at goal changed from 54% at baseline to 80% with the introduction 
of the service33. Furthermore, in a Medicare group of 706 patients, 
28% were found to have ten or more DTPs. As these DTPs were 
identified and resolved, significant improvements in blood pressure 
control and cholesterol were documented with an average cost savings 
of over 1750$ per patient2.
Various studies have demonstrated the positive impact of pharma-
cists’ interventions in the management of chronic diseases, such as 
cardiovascular diseases (CVD) and diabetes, and improvement in 
patient care when pharmacists are located in primary care ambulatory 
clinics working side by side the physicians and nurses17. Particularly, 
the greatest improvement in patient’s clinical outcomes receiving 
CMM services has been observed in patients with medical conditions 
that are extremely costly and are associated with the use of multiple 
medications (hypertension, diabetes, CVD, COPD)12,36,37. Hence, 
patients with these comorbidities are considered as great candidates to 
receive the service. According to the largest database published until 
now14, the total number of 88,556 DTPs was identified and resolved 
in 22,694 patients receiving CMM services in a 4-year period. Out 
of 18,866 patients’ medical conditions that were not at goal at their 
first visit to pharmaceutical care practitioner, 74% of conditions 
improved or remained the same after receiving CMM services (14). 
In a retrospective study from 2004, pharmaceutical care practitioners 
identified 3,407 DTPs in 2,985 patients during their patients’ first 
assessment, out of which 61% had one or more DTPs identified and 
resolved. As a result of pharmaceutical care provision, in one third 
of patients, medical conditions improved17. Ramalho de Oliveira et 
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al 12 showed that pharmacists identified and addressed 38,631 DTPs 
among 9,068 patients during a 10-year period, whereof 80% of DTPs 
were directly resolved with patients, without consulting physicians. 
More than a half of DTPs necessitated inclusion of a new medication 
or dosage increase, while only 16.5% were associated with non-adher-
ence. Rao et al 38 showed that 81% of patients’ DTPs were resolved 
or well managed by pharmacists, while Borges et al 39 resolved 62.7% 
of DTPs in patients with type 2 diabetes. Moreover, CMM services 
have shown the positive impact on individual CV risk factors: blood 
pressure (12,28,31,40), glycated hemoglobin (HbA1c) (30,31,39) and 
LDL cholesterol12,30,40. 
Furthermore, studies have demonstrated the economic and social 
welfare of CMM services17,32,34,41. Patients receiving face-to-face CMM 
services had lower total health expenditures, with the reduction in 
total annual health expenditures exceeding the cost of providing 
CMM services by as high as 12:1, and with the average ratio of 3:1 to 
5:1 (return on investment, ROI )33. A report reviewing the team-based 
medication therapy management system in four clinics revealed that 
spending growth was 11% less in innovation clinics (team-based care 
that incorporates comprehensive medication therapy management) 
than that in 38 non-innovation clinics42. Furthermore, the median 
monthly health care costs per member, measured at five intervals over 
a 15-month period, were significantly lower in innovation than in 
non-innovation sites42. The Ashville project, involving community 
pharmacy based practitioners specially trained to address issues in 
patients with diabetes, asthma, CVD and depression, demonstrated a 
4:1 ROI and a decrease in direct yearly average medical costs between 
$1200 and $1872 per patient 32,43,44.
The value of this service has been recognized by patients who had the 
opportunity to use it as well as by physicians and other health care 
professionals, health plans, employers and payers. Firstly, it is worth 
mentioning that patients benefit not only from improved clinical 
outcomes, but also from having health care professionals who are 
willing and capable to understand their unique medication experi-
ence. Physicians profit by having pharmacotherapy experts managing 
complex therapies side by side, thus enabling them to have more time 
for diagnostics and quality medical care provision33,45. Finally, insurers 
pay only for medications that are appropriate, effective and safe for 
the patient, and are used as intended. 
current Situation of cMM ServiceS acroSS euroPe 
Health systems across Europe have achieved remarkable progress 
in treating life-threatening diseases, yet more effective healthcare 
interventions are needed if we are to improve management of health 
problems in the community. While disparities in healthcare systems 
between the European countries persist, patient-centred practices, in 
which pharmacists are held accountable for patients’ clinical out-
comes, are still underdeveloped and lack inclusion at the primary care 
level. In Europe, in spite of the widespread recognition of the need for 
medication management services, initiation and implementation of 
CMM services are lagging behind. Limited published data on CMM 
services implementation46 confirms that this service has not been 
developed or recognized in Europe, as it has been in the Anglo-Saxon 
countries especially USA and Australia18,47,48. Although supported 
by relevant laws, it seems that governments have not taken an active 
interest in promoting a movement toward pharmacists playing a 
major role in primary health care. The following text will not provide 
an in-depth description of the current situation regarding the status 
of medication management services in Europe, as this has been fully 
described elsewhere14, but rather shed a light on recent advancements 
that have occurred across European countries.
Integration of clinical pharmacist into general practitioner (GP) 
services in Great Britain began in 2015 when the National Health 
Service (NHS) England instigated the initiative and partly funded 
over 400 clinical pharmacists to provide support to almost 700 GP 
surgeries and more than seven million patients 49. To date, over 1,000 
full time equivalent clinical pharmacists provide the service across the 
country with a further 1,500 pharmacist roles planned by 2020 50,51. 
This far-sighted initiative came in response to considerations about 
general practice workforce capacity, where concerns about shortfalls 
in GP numbers have been raised 52. However, it is unclear whether 
the patient care process proposed by Cipolle et al 14,53 is used as the 
theoretical framework to take care of the patients.
Very recent publications from Iceland and Netherlands highlight the 
importance of developing pharmaceutical care practice separately 
from the dispensing process and in close cooperation with physicians, 
at the primary care level48,54. Netherlands is an interesting example of 
community pharmacy having a leading role in pharmaceutical care 
provision, with reimbursements for pharmaceutical care services being 
covered by the Dutch government and health insurance companies14. 
Although it appears that the prerequisites for the implementation of 
medication management services are in place, at present the em-
ployment of CMM services in primary care is suboptimal, if any54. 
Namely, pharmacists lack access to patient information, they are short 
of clinical knowledge and skills, and the working processes of phar-
macists and general practitioners match poorly. Nevertheless, attempts 
have been made to integrate a non-dispensing pharmacist in general 
practice and the results demonstrated favourable outcomes. Albeit, the 
process of care they employed did not follow the patient care process 
proposed by Cipolle et al 14,53. 
Although Iceland undoubtedly embraced the concept of pharmaceuti-
cal care, medication management services are still limited, and serious 
efforts will need to be invested before further development can oc-
cur14. General practitioners are not familiar with pharmaceutical care 
and additionally no such service is offered in pharmacies or primary 
care settings. Efforts have been made to introduce pharmacist-led 
pharmaceutical care into primary care clinics in Iceland in collabora-
tion with GPs, and results showed that GPs would now like to have 
access to a pharmacist on a daily basis48.
In Slovenia, consultations delivered by non-dispensing pharmacists as 
a part of medication review clinics started in 2012, and today they are 
running in over 30 health centres (altogether over 50 clinics available, 
however not running full time)55. However, lack of published data on 
clinical outcomes of this service limits us in making comparisons and 
conclusions on its effectiveness. 
Spain has made progress towards the provision of clinical services 
mainly in community pharmacies. Considering the lack of published 
literature, pharmacists do not seem to be involved in direct patient 
care in ambulatory clinics or in the provision of CMM services. 
However, some very important initiatives have been made to prepare 
pharmacists to provide CMM services and to foster these services. 
The “Universidad de San Jorge” in Zaragoza offers a master program 
in which students are trained to care for real patients in collabora-
tion with other members of the care team, which creatively includes 
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STEPS AND ACTIVITIES HEALTH PROFESSIONAL
PATIENT REFERRAL 
AND RECRUITMENT  
Ø Identify patients who benefit most from the service:
a) Patients who have not reached their therapeutic goal
b) Patients taking very complex dosage regimens
c) Patients who are frequently readmitted to the hospital
d) Patients experiencing adverse drug reactions
e) Patients needing prevention therapy












Assessment of the 
patient’s drug related 
needs
Ø Meet the patient and uncover patient's medication experience
(preferences, expectations and beliefs).
Ø Collect patient specific information: demographic information, social
history (alcohol, tobacco, caffeine) and clinical information (relevant
medical history, medication history, current medication list including
prescription and over-the-counter medications, herbal remedies,
supplements and medications used for a limited period of time, and
relevant laboratory values) including allergies, side-effects and
immunizations.




Ø Determine that all the patient’s medications are properly indicated, the
most effective available, the safest possible, and that the patient is able
and willing to take the medication as intended.
Ø Analyse the assessment data to determine if any drug therapy problems
are present.
Care plan development Ø Identify goals of therapy for each indication managed with drug therapy.
Ø Develop a care plan that includes interventions to resolve current drug
therapy problems, prevent potential drug therapy problems and achieve
goals of therapy.
Ø Discuss and negotiate the care plan with the patient and his prescriber,
ensure patient's and prescriber's understanding and agreement with the
plan, and schedule follow-up evaluation.
Ø Document the care plan which includes all the steps and clinical status
determined for every patient's medical condition.
Follow-up evaluation Ø Make follow-up evaluation for each patient to reassess whether any new
drug therapy problems have developed, monitor patient’s progress
toward the achievement of the goals of therapy, and refine the care plan
to ensure therapy goals are achieved and medication therapy is
optimized.
CARE COORDINATION 




Ø Collaborate and integrate with other health care providers such as
prescribers, medical specialists, pharmacists, care managers, and others,
with the purpose of achieving optimal care for the patient and assuring




specialists and other (e.g. 
nurses)
Table 1. Steps and activities that need to be accomplished to provide effective CMM services
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a psychologist, a philosopher and an anthropologist. Moreover, in 
2012 the “Sociedad Española de Optimización de la Farmacoterapia 
(SEDOF)” was founded in Andalucía with the goal to congregate 
pharmacists interested in developing CMM services56. SEDOF pro-
motes the “Escuela de optimización de la farmacoterapia”, which is 
in its 14th version. These courses include discussions on patient cases 
and reflect on specific aspects of patient care within the framework of 
CMM services.
Croatia is one of the countries where the implementation of com-
prehensive medication management services started only recently. 
Although Croatia embraces the concept of pharmaceutical care prac-
tice, policies and legal regulations supporting the provision of CMM 
services on a much larger scale, still need to be developed. Accord-
ing to the Law on Pharmacy57, Croatian pharmacists are obligated 
to provide pharmaceutical care in cooperation with other health 
care workers. However, the same Law ties pharmaceutical activities 
exclusively to community and hospital pharmacies, and precludes 
pharmacists from providing care at locations where their expertise is 
indispensable, such as nursery homes, health care centres and hospital 
wards. The abovementioned is only one of the existing legal obstacles 
that needs to be addressed prior to CMM services implementation. 
Nevertheless, pharmacy graduates in Croatia are competent in pro-
viding clinical services more than ever before, mainly due to the cur-
riculum reform that has commenced in the academic year 2005/2006 
due to which the focus has shifted from more chemically oriented 
pharmaceutical sciences toward clinically based and patient-focused 
courses. In order to harmonize our study programme with the EU 
Directive 2005/36/EC, Faculty of Pharmacy and Biochemistry 
University of Zagreb (UoZ) introduced an obligatory six-month 
traineeship and new modules (e.g. Pharmacotherapy and Clinical 
Pharmacy, Pharmaceutical Care, Consultation Skills, Health legisla-
tion, Sociology in Pharmacy etc.) in the academic year 2011/2012 
(58). Furthermore, since the academic year 2010/2011, the postgrad-
uate specialist study program “Clinical pharmacy” has been offered 
at the Faculty of Pharmacy and Biochemistry UoZ, and it precedes 
the 3-year Specialization in Clinical Pharmacy assigned from the 
Ministry of Health. All of these changes equipped Croatian pharma-
cists with clinical knowledge and skills needed for engaging in clinical 
activities. Nevertheless, up until now the government did not provide 
any standardized and legal framework allowing for the development 
of strategies to broaden pharmacists’ responsibilities and expand those 
into the integrated health care system. Hence, pharmacists’ educa-
tional requirements for CMM services provision in Croatia still need 
to be defined within the profession itself and subsequently legalized.
On the bright side, a small group of younger pharmacists in Croatia 
is currently taking the lead and creating new services. The CMM 
services are piloted by two pharmacists from the UoZ Faculty of 
Pharmacy and Biochemistry at the primary care clinic, Health 
Centre Zagreb Centre, since January 201846. Until now, this is the 
only county health centre providing CMM services at the primary 
care level in Croatia. This positive development, even if it is small, 
holds promise for the further progression of medication management 
services in Croatia.
The examples of the abovementioned countries showcase that a 
process of comprehensively and rationally managing patients’ medi-
cations is not systematically implemented across European countries 
and that the countries are struggling to find the best solution in that 
endeavour. Due to disparate standing points, resulting from different 
cultural, sociolegal and ethical backgrounds, one cannot foresee a 
direction countries will take and the rate at which the change will be 
occurring. 
In conclusion, for CMM services to become a reality in Europe 
and elsewhere, it is of paramount importance that pharmacists who 
will provide these services have one professional practice as their 
theoretical and ethical foundation. Thus, we will be able to teach to 
this practice and pharmacists will be able to communicate between 
themselves and to others what they do for patients. In addition, only 
then we will be able to evaluate the results of what we do, compare 
between ourselves and improve upon that. That is how all other 
members of the healthcare team work, which reflects the rules of 
patient care worldwide. Moreover, we will need policy to support the 
development and implementation of these services in a manner that 
can be reimbursed, reproducible and sustainable over time. What 
we really need are governments and health plans willing to support 
clinical pharmacists, namely professionals willing and capable to 
provide this service, as it will only live its full potential when we have 
well trained and experienced practitioners. To achieve this, clinical 
pharmacists need not only to expand their clinical knowledge by 
having experience with lots of patients, but also to reflect upon and 
assess these experiences. We will not have clinical experts until we 
have pharmacists that can provide direct patient care as a full-time 
job, caring for as many patients as possible. Only then will they gain 
expertise and exert their full potential. Consequently, we will know 
what this service is able to produce in terms of clinical outcomes and 
healthcare cost reduction. We cannot emphasize enough that the pol-
icy piece is key here. We need innovators, forward thinkers to support 
clinical pharmacists as they work on building their clinical practices 
and expertise. In the end, that is what patients deserve from us.
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